TDSPHARM Co., Ltd. Logo

TDSPHARM Co., Ltd.

Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.

464280 | KO

Overview

Corporate Details

ISIN(s):
KR7464280007
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 253 C동 403호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TDSPHARM Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Transdermal Drug Delivery Systems (TDDS). Founded in 2002, the company leverages its expertise in TDDS technology to produce a range of products, including medical cataplasmas, plasters, and patches. Its portfolio also encompasses over-the-counter (OTC) medicines and cosmetic products. The company is committed to R&D to deliver safe and efficient medicinal products that are absorbed through the skin, with a goal of providing accessible healthcare solutions to consumers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.7 KB
2025-09-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 814.7 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 783.5 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 89.0 KB
2025-04-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.5 KB
2025-04-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 19.6 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 18.0 KB
2025-03-17 00:00
Annual Report
사업보고서 (2024.12)
Korean 437.1 KB
2025-03-17 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1013.2 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 101.9 KB
2025-02-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.1 KB

Automate Your Workflow. Get a real-time feed of all TDSPHARM Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TDSPHARM Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TDSPHARM Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.